Synonyms: B1287 | E5564
Compound class:
Synthetic organic
Comment: Eritoran is a synthetic analogue of lipid A, the bacterial LPS component. It is referred to as a Toll-like receptor 4 (TLR4) antagonist, but rather than direct interaction, eritoran binds to MD-2 and prevents formation of the MD-2.TLR4 protein complex. Thus, eritoran appears to antagonise LPS-induced TLR4 activation.
Eritoran has been investigated as a therapeutic for the management of sepsis, but failed to show sufficient clinical effect [1]. |
|
No information available. |
Summary of Clinical Use ![]() |
Phase 2 clinical trial results were reported by Tidswell et al. (2010) [3]. Despite these positive findings eritoran failed to show significant benefit in a subsequent Phase 2I trial. Note that the clinically used formulation is eritoran tetrasodium, represented by PubChem CID 6450173. |